Lonza Group AG

Lonza Group AG

0QNO · London Exchange

Lonza Group AG (0QNO) is a Medical diagnostics research company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for Lonza Group AG in 2026. The next earnings report is expected on January 27, 2027.

Earnings calendar

Next earnings date

27 Jan 2027

In 160 days

EPS estimate

10.93

Revenue estimate

4.5B

Past earnings

22 Jul 2026
EPS actual
10.10 (-4.7%)
estimate 10.59
Revenue actual
4.2B (-0.4%)
estimate 4.2B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
28 Jan 2026
EPS actual
10.87 (-9.2%)
estimate 11.98
Revenue actual
4.4B (-12.5%)
estimate 5.0B
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Lonza Group AG missed consensus estimates in its latest earnings report, with EPS of USD 10.0992 falling 4.7% short of expectations and revenue of USD 4.18 billion missing estimates by 0.4%. In the previous report, both EPS and revenue also missed expectations.

Dividend calendar

Next ex-dividend

—

Not scheduled

Next payment

—

Not scheduled

Dividend amount

—

Not available

Past dividends

Ex-dividend Payment Amount
12 May 2026 15 May 2026 6.40

EPS (Earnings Per Share)

Revenue

Dividend per share

Company profile

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

Sector
Healthcare
Industry
Medical diagnostics research
Country
Switzerland
Exchange
London Exchange
CEO
Wolfgang Wienand
Employees
17,995
IPO date
07 Mar 2006
ISIN
CH0013841017
Website
lonza.com

Frequently asked questions

When does Lonza Group AG (0QNO) next report earnings?

Lonza Group AG (0QNO) is scheduled to report earnings on January 27, 2027.

What was Lonza Group AG's most recent earnings date?

Lonza Group AG (0QNO) last reported earnings on July 22, 2026.

Where is Lonza Group AG stock listed?

Lonza Group AG (0QNO) is listed on London Exchange.